Sec Form 3 Filing - Dubois-Stringfellow Nathalie @ SANGAMO THERAPEUTICS, INC - 2022-09-09

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Dubois-Stringfellow Nathalie 2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC [ SGMO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP-Chief Development Officer (Last) (First) (Middle) C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD 3. Date of Earliest Transaction (MM/DD/YY) 09/09/2022 (Street) BRISBANE, CA94005 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 94,954( 1 )( 2 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 3.5 ( 3 ) 01/26/2027 Common Stock 54,229 D Stock Option (Right to Buy) $ 20.05 ( 3 ) 01/24/2028 Common Stock 30,000 D Stock Option (Right to Buy) $ 9.03 ( 4 ) 02/25/2029 Common Stock 15,628 D Stock Option (Right to Buy) $ 6.8 ( 5 ) 02/25/2030 Common Stock 55,000 D Stock Option (Right to Buy) $ 11.19 ( 6 ) 02/25/2031 Common Stock 48,000 D Stock Option (Right to Buy) $ 5.9 ( 7 ) 02/25/2032 Common Stock 121,770 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Dubois-Stringfellow Nathalie C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BOULEVARD BRISBANE, CA94005 SVP-Chief Development Officer Signatures Nathalie Dubois-Stringfellow, by /s/ Ron A. Metzger, Attorney-in-Fact 09/19/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes: (a) 9,168 shares of common stock subject to the Reporting Person's February 25, 2020 restricted stock unit ("RSU") grant that will vest in one final annual installment on February 25, 2023 and (b) 16,000 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 8,000 shares on each of February 25, 2023 and 2024. Each such RSU grant vests with respect to 1/3rd of the shares subject to such RSU grant in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. ( 2 )Includes 45,100 shares of common stock subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. ( 3 )Fully vested and exercisable. ( 4 )One-quarter (1/4) of the shares subject to the option vested and became exercisable on the anniversary of the February 25, 2019 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. ( 5 )One-quarter (1/4) of the shares subject to the option vested and became exercisable on the anniversary of the February 25, 2020 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. ( 6 )One-quarter (1/4) of the shares subject to the option vested and became exercisable on the anniversary of the February 25, 2021 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. ( 7 )One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.